February 25, 2022
Accelerating Oligonucleotide Demand: A Force Driving The Contract Manufacturing Market

Since the approval of the first antisense therapy in 1998, oligonucleotides have been in light for their capabilities as therapeutic agents. Oligonucleotides are short synthetic nucleotide chains with immense potential in the diagnosis and treatment of a myriad of disease indications. In addition to therapeutics, these complex molecules act as a significant resource in various